Q5101Injection, zarxio
Published CMS Medicare Part B payment-limit context for Q5101, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$0.353
per 1 MCG · Medicare Part B
Down 0.3%from $0.354 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$0.4755$0.3155
2024-Q4: $0.362; 2025-Q1: $0.357; 2025-Q2: $0.333; 2025-Q3: $0.367; 2025-Q4: $0.458; 2026-Q1: $0.349; 2026-Q2: $0.354; 2026-Q3: $0.353
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Filgrastim ingredient family (FDA data as of August 20, 2026).
Zarxio
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Filgrastim presentations
5 other CMS codesSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J1442 | Inj filgrastim excl biosimil | $1.006 per 1 MCG | $1.016 per 1 MCG | Down 1.0% | ||
| J1447 | Inj tbo filgrastim 1 microg | $0.236 per 1 MCG | $0.246 per 1 MCG | Down 4.1% | ||
| Q5110 | Nivestym | $0.322 per 1 MCG | $0.284 per 1 MCG | Up 13.4% | ||
| Q5125 | Inj, releuko 1 mcg | $0.311 per 1 MCG | $0.32 per 1 MCG | Down 2.8% | ||
| Q5148 | Inj, nyposi 1 mcg | $1.034 per 1 MCG | $1.028 per 1 MCG | Up 0.6% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.